A recent retrospective analysis of data from the MAGNIFY-MS study1 indicates that people with multiple sclerosis (MS) treated with cladribine are able to mount a protective immune response after influenza and varicella zoster vaccination, regardless of the timing of the vaccine relative to the cladribine dose and independent of lymphocyte counts. According to MAGNIFY-MS steering ...
Insights into vaccine readiness for people with MS on cladribine
27 May 2021
Sponsored by Merck Healthcare Pty Ltd